Gregory C. Critchfield, M.D., M.S., served as the CEO of Sera Prognostics, Inc. from 2021 until his retirement in June 2023. With a strong academic background, he earned his M.D. and M.S. in Clinical Investigation from the University of Utah....

Gregory C. Critchfield, M.D., M.S., served as the CEO of Sera Prognostics, Inc. from 2021 until his retirement in June 2023. With a strong academic background, he earned his M.D. and M.S. in Clinical Investigation from the University of Utah. His career focused on advancing medical diagnostics, notably in women's healthcare. During his tenure at Sera Prognostics, he played a crucial role in the commercialization of innovative tests, including the PreTRM test designed for maternal health. While he stepped down from his role as CEO, he remains with the company as a director, showcasing his ongoing commitment to its mission. In 2023, his compensation included a significant severance of $584,000 and a prorated cash bonus of $131,400 reflecting his contributions in a challenging year. Before his retirement, he actively participated in Sera's growth, navigating the business through a dynamic market. Critchfield's experience illustrates a blend of clinical expertise and leadership in the biotech industry, emphasizing a focus on improving health outcomes for women and their families.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Sera Prognostics CEOs

S

Gregory C. Critchfield, M.D., M.S.

Ex-CEO of Sera Prognostics

Education

M.D. from the University of Utah College of Medicine

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

CEO of Sera Prognostics for

11 years 7 months (Nov 2011 - Jun 2023)

Previous Experience

President of Myriad Genetic Laboratories

Rivals

Competitors/colleagues of Gregory C. Critchfield, M.D., M.S.

Holdings

See how much did Gregory C. Critchfield, M.D., M.S. make over time.

At one point in 2021, Gregory C. Critchfield's wealth was tied significantly to the performance of Sera Prognostics, where his insider trading activity was notable. He had holdings valued as high as $8.94 million by August 2021. However, as 2022...

At one point in 2021, Gregory C. Critchfield's wealth was tied significantly to the performance of Sera Prognostics, where his insider trading activity was notable. He had holdings valued as high as $8.94 million by August 2021. However, as 2022 progressed, the value dropped, reaching approximately $1.03 million by December of the same year. This fluctuation highlights the volatility of biotech stocks and the direct impact market conditions can have on executive equity holdings. By 2023, as he approached retirement, the value of his holdings experienced further reduction, underscoring a shift as he transitioned out of a leadership position, with his financial interests adapting accordingly to the changing corporate landscape.

Insider Trading

See recent insider trades of Gregory C. Critchfield, M.D., M.S..

SERA

7,117 shares

SERA

Jun 6, 2024

Received

SERA

62,200 shares

SERA

Mar 7, 2023

Received

Compensation History

See how much did Gregory C. Critchfield, M.D., M.S. make over time.

In 2023, Gregory C. Critchfield's total compensation amounted to $594,025. This figure includes a base salary of $313,023, and a prorated cash bonus of $131,400. His other payments primarily included a severance package of $584,000 resulting from his retirement agreement with Sera Prognostics. It's worth noting that Critchfield did not receive any stock grants or stock options during this time, as his unvested equity awards were forfeited upon his retirement. In comparison, his 2022 compensation was higher at $790,736, which included a cash bonus tied to the company's performance metrics related to their key diagnostic products. This significant shift in compensation illustrates his transitioning role within the company and a reflection of the company's financial dynamics.

Year

2023

Total Compensation

$1.04M

Salary

$313.02K

Board Justification

The compensation philosophy is to provide programs that attract, motivate, reward, and retain highly qualified executives while aligning their interests with those of stockholders.

Bonus

$131.40K

Board Justification

Prorated cash bonus for calendar year 2023 based on a target bonus of 60% of his base salary, awarded in accordance with his Retirement and Transition Agreement.

Other

$594.03K

Board Justification

Other compensation includes $584,000 of severance pay and $10,025 for continued health insurance coverage.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as all unvested stock options and other stock-based equity awards were forfeited as of the Effective Date of his Retirement and Transition Agreement.

Performance Metrics

Performance metrics for the bonus were based on satisfaction of performance goals established by the compensation committee.

Other Sera Prognostics CEOs

Here are other CEOs of Sera Prognostics

Zhenya Lindgardt

CEO of Sera Prognostics

June 2023 - Present